Oklahoma 2023 Regular Session

Oklahoma Senate Bill SB249 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
	3	+	SB249 HFLR Page 1
	4	+	BOLD FACE denotes Committee Amendments. 1
	5	+	2
	6	+	3
	7	+	4
	8	+	5
	9	+	6
	10	+	7
	11	+	8
	12	+	9
	13	+	10
	14	+	11
	15	+	12
	16	+	13
	17	+	14
	18	+	15
	19	+	16
	20	+	17
	21	+	18
	22	+	19
	23	+	20
	24	+	21
	25	+	22
	26	+	23
	27	+	24
3	28
4		-	An Act
5		-	ENROLLED SENATE
	29	+	HOUSE OF REPRESENTATIVES - FLOOR VERSION
	30	+
	31	+	STATE OF OKLAHOMA
	32	+
	33	+	1st Session of the 59th Legislature (2023)
	34	+
	35	+	ENGROSSED SENATE
6	36		BILL NO. 249 By: McCortney of the Senate
7	37
8	38		and
9	39
10	40		Caldwell (Chad) of the
11	41		House
	42	+
	43	+
12	44
13	45
14	46
15	47		An Act relating to controlled dangerous su bstances;
16	48		amending 63 O.S. 2021, Section 2-101, as amended by
17	49		Section 1, Chapter 90, O.S.L. 2021, which relates to
18	50		definitions used in the Uniform Controlled Dangerous
19	51		Substances Act; defining term; amending 63 O.S. 2021,
20	52		Section 2-309, as last amended by Section 1, Chapter
21	53		259, O.S.L 2021, which relates to prescriptions;
22	54		broadening exception from electronic prescription
23	55		requirement; defining term; and declaring an
24	56		emergency.
25	57
26	58
27	59
28	60
29		-	~~SUBJECT: Controlled dangerous substances~~
	61	+
30	62
31	63		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
32		-
33	64		SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-101, as
34	65		amended by Section 1, Chapter 90, O.S.L. 2021, is amended to read as
35	66		follows:
36		-
37	67		Section 2-101. As used in the Uniform Controlled Dangerous
38	68		Substances Act:
	69	+
	70	+	SB249 HFLR Page 2
	71	+	BOLD FACE denotes Committee Amendments. 1
	72	+	2
	73	+	3
	74	+	4
	75	+	5
	76	+	6
	77	+	7
	78	+	8
	79	+	9
	80	+	10
	81	+	11
	82	+	12
	83	+	13
	84	+	14
	85	+	15
	86	+	16
	87	+	17
	88	+	18
	89	+	19
	90	+	20
	91	+	21
	92	+	22
	93	+	23
	94	+	24
39	95
40	96		1. “Administer” means the direct application of a controlled
41	97		dangerous substance, whether by injection, inhala tion, ingestion or
42	98		any other means, to the body of a patient, animal or research
43	99		subject by:
44		-
45		-
46		-	ENR. S. B. NO. 249 Page 2
47	100		a. a practitioner (or, in the presence of the
48	101		practitioner, by the authorized agent of the
49	102		practitioner), or
50		-
51	103		b. the patient or research subject at the direction an d
52	104		in the presence of the practi tioner;
53		-
54	105		2. “Agent” means a peace officer appointed by and who acts on
55	106		behalf of the Director of the Oklahoma Stat e Bureau of Narcotics and
56	107		Dangerous Drugs Control or an authorized person who acts on behalf
57	108		of or at the direction of a person who manufactur es, distributes,
58	109		dispenses, prescribes, administers or uses for scientific purposes
59	110		controlled dangerous substance s but does not include a common or
60	111		contract carrier, public warehouser or employee thereof, or a person
61	112		required to register under the Uniform Controlled Dangerous
62	113		Substances Act;
63		-
64	114		3. “Board” means the Advisory Board to the Director of the
65	115		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
66		-
67	116		4. “Bureau” means the Oklahoma State Bureau of Narcotics and
68	117		Dangerous Drugs Control;
69		-
70	118		5. “Coca leaves” includes cocaine and any compound,
71	119		manufacture, salt, derivative, mixture or preparation of coca
	120	+
	121	+	SB249 HFLR Page 3
	122	+	BOLD FACE denotes Committee Amendments. 1
	123	+	2
	124	+	3
	125	+	4
	126	+	5
	127	+	6
	128	+	7
	129	+	8
	130	+	9
	131	+	10
	132	+	11
	133	+	12
	134	+	13
	135	+	14
	136	+	15
	137	+	16
	138	+	17
	139	+	18
	140	+	19
	141	+	20
	142	+	21
	143	+	22
	144	+	23
	145	+	24
	146	+
72	147		leaves, except derivatives of coca leaves which do not c ontain
73	148		cocaine or ecgonine;
74		-
75	149		6. “Commissioner” or “Director” means the Director of the
76	150		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
77		-
78	151		7. “Control” means to add, remove or change the placem ent of a
79	152		drug, substance or immediate precursor un der the Uniform Controlled
80	153		Dangerous Substances Act;
81		-
82	154		8. “Controlled dangerous substance ” means a drug, substance or
83	155		immediate precursor in Schedules I through V of the Uniform
84	156		Controlled Dangerous Substanc es Act or any drug, substance or
85	157		immediate precursor listed either temporarily or permanently as a
86	158		federally controlled substance. Any confli ct between state and
87	159		federal law with regard to the particular schedule in which a
88	160		substance is listed shall be re solved in favor of state law;
89		-
90		-	ENR. S. B. NO. 249 Page 3
91		-
92	161		9. “Counterfeit substance” means a controlled substance which,
93	162		or the container or labeling of which without au thorization, bears
94	163		the trademark, trade name or other identifying marks, imprint,
95	164		number or device or any likeness thereof of a manufacturer,
96	165		distributor or dispens er other than the person who in fact
97	166		manufactured, distribute d or dispensed the substance;
98		-
99	167		10. “Deliver” or “delivery” means the actual, constructive or
100	168		attempted transfer from one person to another of a c ontrolled
101	169		dangerous substance or drug paraphernali a, whether or not there is
102	170		an agency relationship;
	171	+
	172	+	SB249 HFLR Page 4
	173	+	BOLD FACE denotes Committee Amendments. 1
	174	+	2
	175	+	3
	176	+	4
	177	+	5
	178	+	6
	179	+	7
	180	+	8
	181	+	9
	182	+	10
	183	+	11
	184	+	12
	185	+	13
	186	+	14
	187	+	15
	188	+	16
	189	+	17
	190	+	18
	191	+	19
	192	+	20
	193	+	21
	194	+	22
	195	+	23
	196	+	24
103	197
104	198		11. “Dispense” means to deliver a contro lled dangerous
105	199		substance to an ultimate user or human research subject by or
106	200		pursuant to the lawful order of a pra ctitioner including the
107	201		prescribing, administering , packaging, labeling or compounding
108	202		necessary to prepare the substance for such distributio n.
109	203		“Dispenser” is a practitioner who delivers a controlled dangerous
110	204		substance to an ultimate user or human resea rch subject;
111		-
112	205		12. “Distribute” means to deliver other than by administering
113	206		or dispensing a controlled dangerou s substance;
114		-
115	207		13. “Distributor” means a commercial entity engaged in the
116	208		distribution or reverse distribution of narcotics and dangerous
117	209		drugs and who complies with all regulations promulgated by the
118	210		federal Drug Enforcement Administration and the Oklahoma State
119	211		Bureau of Narcotics and Dangerous Drugs Control;
120		-
121	212		14. “Drug” means articles:
122		-
123	213		a. recognized in the official United States
124	214		Pharmacopoeia, official Homeopathic Pharmacopoeia of
125	215		the United States, or official National Formulary, or
126	216		any supplement to any of them,
127		-
128	217		b. intended for use in the diagnosis, cure, mitigation,
129	218		treatment or prevention of disease in man or other
130	219		animals,
131		-
132		-
133		-	ENR. S. B. NO. 249 Page 4
134	220		c. other than food, intended to affect the structure or
135	221		any function of the body of man or other animals, and
136	222
	223	+	SB249 HFLR Page 5
	224	+	BOLD FACE denotes Committee Amendments. 1
	225	+	2
	226	+	3
	227	+	4
	228	+	5
	229	+	6
	230	+	7
	231	+	8
	232	+	9
	233	+	10
	234	+	11
	235	+	12
	236	+	13
	237	+	14
	238	+	15
	239	+	16
	240	+	17
	241	+	18
	242	+	19
	243	+	20
	244	+	21
	245	+	22
	246	+	23
	247	+	24
	248	+
137	249		d. intended for use as a component of any article
138	250		specified in this paragraph;
139		-
140	251		provided, however, the term “drug” drug does not include devices or
141	252		their components, parts or accessories;
142		-
143	253		15. “Drug-dependent person” means a person who is using a
144	254		controlled dangerous substance and who is in a state of psych ic or
145	255		physical dependence, or both, arising from administration of that
146	256		controlled dangerous substance on a continuous basis. Drug
147	257		dependence is characterized by b ehavioral and other responses which
148	258		include a strong compulsi on to take the substance on a c ontinuous
149	259		basis in order to experience its psychic effects, or to avoid the
150	260		discomfort of its absence;
151		-
152	261		16. “Home care agency” means any sole proprietorship,
153	262		partnership, association, corporation, or other organization which
154	263		administers, offers, or provide s home care services, for a fee or
155	264		pursuant to a contract for such services, to clients in their place
156	265		of residence;
157		-
158	266		17. “Home care services” means skilled or pers onal care
159	267		services provided to clients in their place of resi dence for a fee;
160		-
161	268		18. “Hospice” means a centrally administered, nonprofit or
162	269		profit, medically directed, nurse -coordinated program which provides
163	270		a continuum of home and inpatient care for the te rminally ill
164	271		patient and the patient’s family. Such term sha ll also include a
165	272		centrally administered, nonprofit or profit, medically directed,
	273	+
	274	+	SB249 HFLR Page 6
	275	+	BOLD FACE denotes Committee Amendments. 1
	276	+	2
	277	+	3
	278	+	4
	279	+	5
	280	+	6
	281	+	7
	282	+	8
	283	+	9
	284	+	10
	285	+	11
	286	+	12
	287	+	13
	288	+	14
	289	+	15
	290	+	16
	291	+	17
	292	+	18
	293	+	19
	294	+	20
	295	+	21
	296	+	22
	297	+	23
	298	+	24
	299	+
166	300		nurse-coordinated program if such program is licensed pursuant to
167	301		the provisions of the Uniform Controlled Dange rous Substances Act.
168	302		A hospice program offers palliative and supportive care to meet the
169	303		special needs arising out of the physical, emotional and spiritual
170	304		stresses which are experienced during the final stages of illness
171	305		and during dying and bereavement. This care is available twenty-
172	306		four (24) hours a day, seven (7) days a week, and is provide d on the
173	307		basis of need, regardless of ability to pay. “Class A” Hospice
174	308		refers to Medicare certified hospices. “Class B” refers to all
175	309		other providers of hospice services;
176		-
177		-	ENR. S. B. NO. 249 Page 5
178		-
179	310		19. “Imitation controlled substance” means a substance that is
180	311		not a controlled dangerous substance, which by dosage unit
181	312		appearance, color, shape, size, markings or by representations made,
182	313		would lead a reasonable person to believe that the sub stance is a
183	314		controlled dangerous substance. In the event the appearance of the
184	315		dosage unit is not reasonably sufficient to establish that the
185	316		substance is an “imitation controlled substance ” imitation
186	317		controlled substance , the court or autho rity concerned should
187	318		consider, in addition to all other factors, the following factors as
188	319		related to “representations made” in determining whether the
189	320		substance is an “imitation controlled substance ” imitation
190	321		controlled substance :
191	322
	323	+	SB249 HFLR Page 7
	324	+	BOLD FACE denotes Committee Amendments. 1
	325	+	2
	326	+	3
	327	+	4
	328	+	5
	329	+	6
	330	+	7
	331	+	8
	332	+	9
	333	+	10
	334	+	11
	335	+	12
	336	+	13
	337	+	14
	338	+	15
	339	+	16
	340	+	17
	341	+	18
	342	+	19
	343	+	20
	344	+	21
	345	+	22
	346	+	23
	347	+	24
	348	+
192	349		a. statements made by an owner or by any other person in
193	350		control of the substance concerning the n ature of the
194	351		substance, or its use or effect,
195		-
196	352		b. statements made to the recipient that the substance
197	353		may be resold for inord inate profit,
198		-
199	354		c. whether the substance is packaged in a manner normally
200	355		used for illicit controlled substances,
201		-
202	356		d. evasive tactics or actions utilized by the owner or
203	357		person in control of the substance to avoid detection
204	358		by law enforcement authorities,
205		-
206	359		e. prior convictions, if any, of an owner, or any other
207	360		person in control of the object, under state or
208	361		federal law related to controlled substances or frau d,
209	362		and
210		-
211	363		f. the proximity of the substances to controlled
212	364		dangerous substances;
213		-
214	365		20. “Immediate precursor” means a substance which the Director
215	366		has found to be and by regulatio n designates as being the principal
216	367		compound commonly used or produced primarily f or use, and which is
217	368		an immediate chemical intermediary used, or likely to be used, in
218	369		the manufacture of a controlled dangerous substance, the control of
219	370		which is necessary to prevent, curtail or limit such manufacture;
220		-
221		-	ENR. S. B. NO. 249 Page 6
222		-
223	371		21. “Laboratory” means a laboratory approved by the Director as
224	372		proper to be entrusted with the custody of controlled dangerous
	373	+
	374	+	SB249 HFLR Page 8
	375	+	BOLD FACE denotes Committee Amendments. 1
	376	+	2
	377	+	3
	378	+	4
	379	+	5
	380	+	6
	381	+	7
	382	+	8
	383	+	9
	384	+	10
	385	+	11
	386	+	12
	387	+	13
	388	+	14
	389	+	15
	390	+	16
	391	+	17
	392	+	18
	393	+	19
	394	+	20
	395	+	21
	396	+	22
	397	+	23
	398	+	24
	399	+
225	400		substances and the use of controlled dangerous substances for
226	401		scientific and medical purposes and for purposes of instruction;
227		-
228	402		22. “Manufacture” means the production, preparation,
229	403		propagation, compounding or processing of a controlled dangerous
230	404		substance, either directly or indirectly by extraction from
231	405		substances of natural or synth etic origin, or independently by means
232	406		of chemical synthesis or by a combination o f extraction and chemical
233	407		synthesis. “Manufacturer” includes any person who packages,
234	408		repackages or labels any container of any controlled dangerous
235	409		substance, except practi tioners who dispense or compound
236	410		prescription orders for delivery to the ultimate consumer;
237		-
238	411		23. “Marijuana” means all parts of the plant Cannabis sativa
239	412		L., whether growing or not; the seeds thereof; the resin extracted
240	413		from any part of such plant; and ev ery compound, manufacture, salt,
241	414		derivative, mixture or preparation of such plant, its seeds or
242	415		resin, but shall not include:
243		-
244	416		a. the mature stalks of such plant or fiber produced from
245	417		such stalks,
246		-
247	418		b. oil or cake made from the seeds of such plant
248	419		including cannabidiol derived from the seeds of the
249	420		marijuana plant,
250		-
251	421		c. any other compound, manufacture, salt, derivative,
252	422		mixture or preparation of such mature stalks (except
	423	+
	424	+	SB249 HFLR Page 9
	425	+	BOLD FACE denotes Committee Amendments. 1
	426	+	2
	427	+	3
	428	+	4
	429	+	5
	430	+	6
	431	+	7
	432	+	8
	433	+	9
	434	+	10
	435	+	11
	436	+	12
	437	+	13
	438	+	14
	439	+	15
	440	+	16
	441	+	17
	442	+	18
	443	+	19
	444	+	20
	445	+	21
	446	+	22
	447	+	23
	448	+	24
	449	+
253	450		the resin extracted therefrom) including cannabidiol
254	451		derived from mature stalks, fiber, oi l or cake,
255		-
256	452		d. the sterilized seed of such plant which is incapable
257	453		of germination,
258		-
259	454		e. for any person participating in a clinical trial to
260	455		administer cannabidiol for the treatment of severe
261	456		forms of epilepsy pursuant to Section 2 -802 of this
262	457		title, a drug or substance approved by the federal
263		-
264		-	ENR. S. B. NO. 249 Page 7
265	458		Food and Drug Administration for use by those
266	459		participants,
267		-
268	460		f. for any person or the parents, legal guardians or
269	461		caretakers of the person who have received a written
270	462		certification from a physician licensed in this state
271	463		that the person has been diagnosed by a physician as
272	464		having Lennox-Gastaut syndrome, Dravet syndrome, also
273	465		known as Severe Myoclonic Epilepsy of Infancy, or any
274	466		other severe form of epilepsy that is not adequately
275	467		treated by traditional medical therapies, spasticity
276	468		due to multiple sclerosis or due to paraplegia,
277	469		intractable nausea and vomiting, appetite stimulation
278	470		with chronic wasting diseases, the substance
279	471		cannabidiol, a nonpsychoactive cannabinoid, found in
280	472		the plant Cannabis sativa L. or any other pre paration
281	473		thereof, that has a tetrahydrocannabinol concentration
	474	+
	475	+	SB249 HFLR Page 10
	476	+	BOLD FACE denotes Committee Amendments. 1
	477	+	2
	478	+	3
	479	+	4
	480	+	5
	481	+	6
	482	+	7
	483	+	8
	484	+	9
	485	+	10
	486	+	11
	487	+	12
	488	+	13
	489	+	14
	490	+	15
	491	+	16
	492	+	17
	493	+	18
	494	+	19
	495	+	20
	496	+	21
	497	+	22
	498	+	23
	499	+	24
	500	+
282	501		of not more than three-tenths of one percent (0.3%)
283	502		and that is delivered to the patient in the form of a
284	503		liquid,
285		-
286	504		g. any federal Food and Drug Administration -approved
287	505		cannabidiol drug or subst ance, or
288		-
289	506		h. industrial hemp, from the plant Cannabis sativa L. and
290	507		any part of such plant, whether growing or not, with a
291	508		delta-9 tetrahydrocannabinol concentration of not more
292	509		than three-tenths of one percent (0.3%) on a dry
293	510		weight basis which shall only be grown pursuant to the
294	511		Oklahoma Industrial Hemp Program and may be shipped
295	512		intrastate and interstate;
296		-
297	513		24. “Medical purpose” means an intention to utilize a
298	514		controlled dangerous substance for physical or mental treatment, for
299	515		diagnosis, or for the preven tion of a disease condition not in
300	516		violation of any state or federal law and not f or the purpose of
301	517		satisfying physiological or psychological dependence or other abuse;
302		-
303	518		25. “Mid-level practitioner” means an Advanced Practice
304	519		Registered Nurse as defined an d within parameters specified in
305	520		Section 567.3a of Title 59 of the Oklahoma Statut es, or a certified
306	521		animal euthanasia technician as defined in Section 698.2 of Title 59
307		-
308		-	ENR. S. B. NO. 249 Page 8
309	522		of the Oklahoma Statutes, or an animal control officer registered by
310	523		the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
311	524		under subsection B of Section 2 -301 of this title within the
	525	+
	526	+	SB249 HFLR Page 11
	527	+	BOLD FACE denotes Committee Amendments. 1
	528	+	2
	529	+	3
	530	+	4
	531	+	5
	532	+	6
	533	+	7
	534	+	8
	535	+	9
	536	+	10
	537	+	11
	538	+	12
	539	+	13
	540	+	14
	541	+	15
	542	+	16
	543	+	17
	544	+	18
	545	+	19
	546	+	20
	547	+	21
	548	+	22
	549	+	23
	550	+	24
	551	+
312	552		parameters of such officer ’s duties under Sections 501 through 508
313	553		of Title 4 of the Oklahoma Statutes;
314		-
315	554		26. “Narcotic drug” means any of the fol lowing, whether
316	555		produced directly or indirectly by extraction from substances of
317	556		vegetable origin, or independently by means of chemical synthesis,
318	557		or by a combination of extraction and chemical synthesis:
319		-
320	558		a. opium, coca leaves and opiates,
321		-
322	559		b. a compound, manufacture, salt, derivative or
323	560		preparation of opium, coca leaves or opiates,
324		-
325	561		c. cocaine, its salts, optical and geometric isomers, and
326	562		salts of isomers,
327		-
328	563		d. ecgonine, its derivatives, their salts, isomers and
329	564		salts of isomers, and
330		-
331	565		e. a substance, and any compound, manufacture, salt,
332	566		derivative or preparation thereof, which is chemicall y
333	567		identical with any of the substances referred to in
334	568		subparagraphs a through d of this paragraph, except
335	569		that the words “narcotic drug” as used in Section 2 -
336	570		101 et seq. of this title shall not include
337	571		decocainized coca leaves or extracts of coca leaves,
338	572		which extracts do not contain cocaine or ecgonine;
339		-
340	573		27. “Opiate” or “opioid” means any Schedule II, III, IV or V
341	574		substance having an addiction -forming or addiction -sustaining
342	575		liability similar to morphine or being capable of conversion into a
	576	+
	577	+	SB249 HFLR Page 12
	578	+	BOLD FACE denotes Committee Amendments. 1
	579	+	2
	580	+	3
	581	+	4
	582	+	5
	583	+	6
	584	+	7
	585	+	8
	586	+	9
	587	+	10
	588	+	11
	589	+	12
	590	+	13
	591	+	14
	592	+	15
	593	+	16
	594	+	17
	595	+	18
	596	+	19
	597	+	20
	598	+	21
	599	+	22
	600	+	23
	601	+	24
	602	+
343	603		drug having such addiction-forming or addiction-sustaining
344	604		liability. The terms do not include, unless specifically designated
345	605		as controlled under the Uniform Controlled Dangerous Substan ces Act,
346	606		the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its
347	607		salts (dextromethorphan). The terms do include the racemic and
348	608		levorotatory forms;
349		-
350		-
351		-	ENR. S. B. NO. 249 Page 9
352	609		28. “Opium poppy” means the plant of the species Papaver
353	610		somniferum L., except the seeds thereof ;
354		-
355	611		29. “Peace officer” means a police officer, sheriff, deput y
356	612		sheriff, district attorney’s investigator, investigator from the
357	613		Office of the Attorney General, or an y other person elected or
358	614		appointed by law to enforce any of the criminal laws of this stat e
359	615		or of the United States;
360		-
361	616		30. “Person” means an individual, corporation, governm ent or
362	617		governmental subdivision or agency, business trust, estate, trust,
363	618		partnership or association, or any other legal entity;
364		-
365	619		31. “Poppy straw” means all parts, except th e seeds, of the
366	620		opium poppy, after mowing;
	621	+	32. “Practitioner” means:
	622	+	a. (1) a medical doctor or osteopathic physician,
	623	+	(2) a dentist,
	624	+	(3) a podiatrist,
	625	+	(4) an optometrist,
	626	+	(5) a veterinarian,
367	627
368		-	32. “Practitioner” means:
369		-
370		-	a. (1) a medical doctor or osteopathic physician,
371		-
372		-	(2) a dentist,
373		-
374		-	(3) a podiatrist,
375		-
376		-	(4) an optometrist,
377		-
378		-	(5) a veterinarian,
	628	+	SB249 HFLR Page 13
	629	+	BOLD FACE denotes Committee Amendments. 1
	630	+	2
	631	+	3
	632	+	4
	633	+	5
	634	+	6
	635	+	7
	636	+	8
	637	+	9
	638	+	10
	639	+	11
	640	+	12
	641	+	13
	642	+	14
	643	+	15
	644	+	16
	645	+	17
	646	+	18
	647	+	19
	648	+	20
	649	+	21
	650	+	22
	651	+	23
	652	+	24
379	653
380	654		(6) a physician assistant or Advanced Practice
381	655		Registered Nurse under the supervision of a
382	656		licensed medical doctor or osteop athic physician,
383		-
384	657		(7) a scientific investigator, or
385		-
386	658		(8) any other person,
387		-
388	659		licensed, registered or otherwi se permitted to
389	660		prescribe, distribute, dispense, conduct research with
390	661		respect to, use for scientific purposes or administer
391	662		a controlled dangerous subs tance in the course o f
392	663		professional practice or research in this state, or
393		-
394		-
395		-	ENR. S. B. NO. 249 Page 10
396	664		b. a pharmacy, hospital, labo ratory or other institution
397	665		licensed, registered or otherwise permitted to
398	666		distribute, dispense, conduct research with respect
399	667		to, use for scientific pu rposes or administer a
400	668		controlled dangerous substance in the course of
401	669		professional practice or research in this state;
402		-
403	670		33. “Production” includes the manufacture, planting,
404	671		cultivation, growing or harvesting of a controlled dangerous
405	672		substance;
406		-
407	673		34. “State” means the State of Oklahoma or any other state of
408	674		the United States;
409		-
410	675		35. “Ultimate user” means a person who lawfully possesses a
411	676		controlled dangerous substance for the person ’s own use or for the
412	677		use of a member of the person’s household or for adminis tration to
	678	+
	679	+	SB249 HFLR Page 14
	680	+	BOLD FACE denotes Committee Amendments. 1
	681	+	2
	682	+	3
	683	+	4
	684	+	5
	685	+	6
	686	+	7
	687	+	8
	688	+	9
	689	+	10
	690	+	11
	691	+	12
	692	+	13
	693	+	14
	694	+	15
	695	+	16
	696	+	17
	697	+	18
	698	+	19
	699	+	20
	700	+	21
	701	+	22
	702	+	23
	703	+	24
	704	+
413	705		an animal owned by the person or by a member of the person ’s
414	706		household;
415		-
416	707		36. “Drug paraphernalia” means all equipment, products and
417	708		materials of any kind which are used, intended for u se, or fashioned
418	709		specifically for use in planting, propagatin g, cultivating, growi ng,
419	710		harvesting, manufacturing, compounding, converting, producing,
420	711		processing, preparing, testing, analyzing, packaging, repackaging,
421	712		storing, containing, concealing, injecti ng, ingesting, inhaling or
422	713		otherwise introducing into the hum an body, a controlled dangerous
423	714		substance in violation of the Uniform Controlled Dangerous
424	715		Substances Act including, but not limited to:
425		-
426	716		a. kits used, intended for use, or fashioned specifically
427	717		for use in planting, propagating, cultivating, growing
428	718		or harvesting of any specie s of plant which is a
429	719		controlled dangerous substance or from which a
430	720		controlled dangerous substance can be derived,
431		-
432	721		b. kits used, intended for use, or fashioned specifically
433	722		for use in manufacturing, compounding, converting,
434	723		producing, processing or prepar ing controlled
435	724		dangerous substances,
436		-
437		-
438		-	ENR. S. B. NO. 249 Page 11
439	725		c. isomerization devices used, intended for use, or
440	726		fashioned specifically for use in increasing the
441	727		potency of any species of plant whic h is a controlled
442	728		dangerous substance,
443	729
	730	+	SB249 HFLR Page 15
	731	+	BOLD FACE denotes Committee Amendments. 1
	732	+	2
	733	+	3
	734	+	4
	735	+	5
	736	+	6
	737	+	7
	738	+	8
	739	+	9
	740	+	10
	741	+	11
	742	+	12
	743	+	13
	744	+	14
	745	+	15
	746	+	16
	747	+	17
	748	+	18
	749	+	19
	750	+	20
	751	+	21
	752	+	22
	753	+	23
	754	+	24
	755	+
444	756		d. testing equipment used, intended for use , or fashioned
445	757		specifically for use in identifying, or in analyzing
446	758		the strength, effectiveness or purity of controlled
447	759		dangerous substances,
448		-
449	760		e. scales and balances used, int ended for use, or
450	761		fashioned specifically for use in weighing or
451	762		measuring controlled dangerous substances,
452		-
453	763		f. diluents and adulterants, such as quinine
454	764		hydrochloride, mannitol, mannite, dextrose and
455	765		lactose, used, intended for use, or fashioned
456	766		specifically for use in cutting controlled dangerous
457	767		substances,
458		-
459	768		g. separation gins and sifte rs used, intended for use, or
460	769		fashioned specifically for use in removing twigs and
461	770		seeds from, or in otherwise cleaning or refining,
462	771		marijuana,
463		-
464	772		h. blenders, bowls, containers , spoons and mixing devices
465	773		used, intended for use, or fashio ned specifically for
466	774		use in compounding controlled dangerous substances,
467		-
468	775		i. capsules, balloons, envelopes and other containers
469	776		used, intended for use, or fashioned specifically for
470	777		use in packaging small quantities of controlled
471	778		dangerous substances,
472	779
	780	+	SB249 HFLR Page 16
	781	+	BOLD FACE denotes Committee Amendments. 1
	782	+	2
	783	+	3
	784	+	4
	785	+	5
	786	+	6
	787	+	7
	788	+	8
	789	+	9
	790	+	10
	791	+	11
	792	+	12
	793	+	13
	794	+	14
	795	+	15
	796	+	16
	797	+	17
	798	+	18
	799	+	19
	800	+	20
	801	+	21
	802	+	22
	803	+	23
	804	+	24
	805	+
473	806		j. containers and other ob jects used, intended for use,
474	807		or fashioned specifically for use in parenterally
475	808		injecting controlled dangerous substances into the
476	809		human body,
477		-
478	810		k. hypodermic syringes, needles and other objects used,
479	811		intended for use, or fashioned speci fically for use in
480	812		parenterally injecting controlled dangerous substances
481		-
482		-	ENR. S. B. NO. 249 Page 12
483	813		into the human body except as authorized by Section 3
484	814		of this act 2-1101 of this title,
485		-
486	815		l. objects used, intended for use , or fashioned
487	816		specifically for use in ingesting, inhaling or
488	817		otherwise introducing marijuan a, cocaine, hashish or
489	818		hashish oil into the human body, such as:
490		-
491	819		(1) metal, wooden, acrylic, glass, stone, plastic or
492	820		ceramic pipes with or without screens, permane nt
493	821		screens, hashish heads or punctured metal bowls,
494		-
495	822		(2) water pipes,
496		-
497	823		(3) carburetion tubes and devices,
498		-
499	824		(4) smoking and carburetion masks,
500		-
501	825		(5) roach clips, meaning objects used to hold burning
502	826		material, such as a marijuana cigarette, that has
503	827		become too small or too short to be held in the
504	828		hand,
505		-
506	829		(6) miniature cocaine spoons and cocaine vials,
507	830
	831	+	SB249 HFLR Page 17
	832	+	BOLD FACE denotes Committee Amendments. 1
	833	+	2
	834	+	3
	835	+	4
	836	+	5
	837	+	6
	838	+	7
	839	+	8
	840	+	9
	841	+	10
	842	+	11
	843	+	12
	844	+	13
	845	+	14
	846	+	15
	847	+	16
	848	+	17
	849	+	18
	850	+	19
	851	+	20
	852	+	21
	853	+	22
	854	+	23
	855	+	24
	856	+
508	857		(7) chamber pipes,
509		-
510	858		(8) carburetor pipes,
511		-
512	859		(9) electric pipes,
513		-
514	860		(10) air-driven pipes,
515		-
516	861		(11) chillums,
517		-
518	862		(12) bongs, or
519		-
520	863		(13) ice pipes or chillers,
521		-
522	864		m. all hidden or novelty pipes, and
523		-
524		-
525		-	ENR. S. B. NO. 249 Page 13
526	865		n. any pipe that has a tobacco bowl or chamber of less
527	866		than one-half (1/2) inch in diameter in which there is
528	867		any detectable residue of any controlled dangerous
529	868		substance as defined in this section or any other
530	869		substances not legal for possessio n or use;
531		-
532	870		provided, however, the term “drug paraphernalia” drug paraphernalia
533	871		shall not include separation gins intended for use in preparing tea
534	872		or spice, clamps used for constructing electrical equipment, water
535	873		pipes designed for ornamentation in which n o detectable amount of an
536	874		illegal substance is found or p ipes designed and used solely for
537	875		smoking tobacco, traditional pipes of an American Indian tribal
538	876		religious ceremony, or antique pipes that are thirty (30) years of
539	877		age or older;
	878	+	37. a. “Synthetic controlled substance” means a substance:
540	879
541		-	37. a. “Synthetic controlled substance” means a substance:
	880	+	SB249 HFLR Page 18
	881	+	BOLD FACE denotes Committee Amendments. 1
	882	+	2
	883	+	3
	884	+	4
	885	+	5
	886	+	6
	887	+	7
	888	+	8
	889	+	9
	890	+	10
	891	+	11
	892	+	12
	893	+	13
	894	+	14
	895	+	15
	896	+	16
	897	+	17
	898	+	18
	899	+	19
	900	+	20
	901	+	21
	902	+	22
	903	+	23
	904	+	24
542	905
543	906		(1) the chemical structure of which is substantially
544	907		similar to the chemical structure of a controlled
545	908		dangerous substance in Schedule I or II,
546		-
547	909		(2) which has a stimulant, depressant, or
548	910		hallucinogenic effect on the central nervous
549	911		system that is substantially similar to or
550	912		greater than the stimulant, depressant or
551	913		hallucinogenic effect on the central nervous
552	914		system of a controlled dangerous substance in
553	915		Schedule I or II, or
554		-
555	916		(3) with respect to a particular person, wh ich such
556	917		person represents or intends to have a stimulant,
557	918		depressant, or hallucinogenic effect on the
558	919		central nervous system that is substantially
559	920		similar to or greater than the stimulant,
560	921		depressant, or hallucinogenic effect on the
561	922		central nervous system of a controlled dangerous
562	923		substance in Schedule I or II.
563		-
564	924		b. The designation of gamma butyrolactone or any other
565	925		chemical as a precursor, pursuant to Section 2 -322 of
566	926		this title, does not preclude a finding pursuant to
567		-
568		-	ENR. S. B. NO. 249 Page 14
569	927		subparagraph a of this paragraph that the chemical is
570	928		a synthetic controlled substance.
571		-
572	929		c. “Synthetic controlled substance” does not include:
573	930
	931	+	SB249 HFLR Page 19
	932	+	BOLD FACE denotes Committee Amendments. 1
	933	+	2
	934	+	3
	935	+	4
	936	+	5
	937	+	6
	938	+	7
	939	+	8
	940	+	9
	941	+	10
	942	+	11
	943	+	12
	944	+	13
	945	+	14
	946	+	15
	947	+	16
	948	+	17
	949	+	18
	950	+	19
	951	+	20
	952	+	21
	953	+	22
	954	+	23
	955	+	24
	956	+
574	957		(1) a controlled dangerous substance,
575		-
576	958		(2) any substance for which there is an approved new
577	959		drug application,
578		-
579	960		(3) with respect to a particular person an y
580	961		substance, if an exemption is in effect for
581	962		investigational use, for that person under the
582	963		provisions of Section 505 of the Federal Food,
583	964		Drug and Cosmetic Act, Title 21 of the United
584	965		States Code, Section 355, to the extent c onduct
585	966		with respect to such s ubstance is pursuant to
586	967		such exemption, or
587		-
588	968		(4) any substance to the extent not intended for
589	969		human consumption before such an exemption takes
590	970		effect with respect to that substance.
591		-
592	971		d. Prima facie evidence that a substance contai ning
593	972		salvia divinorum has bee n enhanced, concentrated or
594	973		chemically or physically altere d shall give rise to a
595	974		rebuttable presumption that the substance is a
596	975		synthetic controlled substance;
597		-
598	976		38. “Tetrahydrocannabinols ” means all substances that have been
599	977		chemically synthesized to emul ate the tetrahydrocannabinols of
600	978		marijuana;
601		-
602	979		39. “Isomer” means the optical isomer, except as used in
603	980		subsections C and F of Section 2-204 of this title and paragraph 4
	981	+
	982	+	SB249 HFLR Page 20
	983	+	BOLD FACE denotes Committee Amendments. 1
	984	+	2
	985	+	3
	986	+	4
	987	+	5
	988	+	6
	989	+	7
	990	+	8
	991	+	9
	992	+	10
	993	+	11
	994	+	12
	995	+	13
	996	+	14
	997	+	15
	998	+	16
	999	+	17
	1000	+	18
	1001	+	19
	1002	+	20
	1003	+	21
	1004	+	22
	1005	+	23
	1006	+	24
	1007	+
604	1008		of subsection A of Section 2 -206 of this title. As used i n
605	1009		subsections C and F of Sect ion 2-204 of this title, “isomer” isomer
606	1010		means the optical, p ositional or geometric isomer. As used in
607	1011		paragraph 4 of subsection A of Section 2-206 of this title, the term
608	1012		“isomer” isomer means the optical or geometric isomer;
609		-
610		-
611		-	ENR. S. B. NO. 249 Page 15
612	1013		40. “Hazardous materials” means materials, whether solid,
613	1014		liquid or gas, which are toxic to human, animal, aquatic or plant
614	1015		life, and the disposal of which materials is controlled by state or
615	1016		federal guidelines;
616		-
617	1017		41. “Anhydrous ammonia” means any substance that exhibi ts
618	1018		cryogenic evaporative behavior and tests positive for ammonia;
619		-
620	1019		42. “Acute pain” means pain, whether resulting from disease,
621	1020		accidental or intentional trauma or other cause, that the
622	1021		practitioner reasonably expects to last only a short period of time.
623	1022		“Acute pain” Acute pain does not include chronic pain, pain being
624	1023		treated as part of cancer care, h ospice or other end-of-life care,
625	1024		or pain being treated as part o f palliative care;
626		-
627	1025		43. “Chronic pain” means pain that persists beyond the usual
628	1026		course of an acute dis ease or healing of an injury. “Chronic pain”
629	1027		Chronic pain may or may not be associated with an acute or chronic
630	1028		pathologic process that causes continuous or intermit tent pain over
631	1029		months or years;
632		-
633	1030		44. “Initial prescription ” means a prescription issued to a
634	1031		patient who:
	1032	+
	1033	+	SB249 HFLR Page 21
	1034	+	BOLD FACE denotes Committee Amendments. 1
	1035	+	2
	1036	+	3
	1037	+	4
	1038	+	5
	1039	+	6
	1040	+	7
	1041	+	8
	1042	+	9
	1043	+	10
	1044	+	11
	1045	+	12
	1046	+	13
	1047	+	14
	1048	+	15
	1049	+	16
	1050	+	17
	1051	+	18
	1052	+	19
	1053	+	20
	1054	+	21
	1055	+	22
	1056	+	23
	1057	+	24
635	1058
636	1059		a. has never previously been issued a prescriptio n for
637	1060		the drug or its pharmaceu tical equivalent in the past
638	1061		year, or
639		-
640	1062		b. requires a prescription for t he drug or its
641	1063		pharmaceutical equivalent due to a surgical procedure
642	1064		or new acute event and ha s previously had a
643	1065		prescription for the drug or its pharmaceu tical
644	1066		equivalent within the pas t year.
645		-
646	1067		When determining whether a patient was previously issued a
647	1068		prescription for a drug or its pharmaceutical equivalent, the
648	1069		practitioner shall consult with the patient and review the medical
649	1070		record and prescription monit oring information of the patien t;
650		-
651	1071		45. “Patient-provider agreement” means a written contract or
652	1072		agreement that is executed between a practitioner and a patient,
653		-
654		-	ENR. S. B. NO. 249 Page 16
655	1073		prior to the commencement of treat ment for chronic pain using an
656	1074		opioid drug as a means to:
657		-
658	1075		a. explain the possible risk of de velopment of physical
659	1076		or psychological dependence in the patient and p revent
660	1077		the possible development of addiction,
661		-
662	1078		b. document the understanding of both the practi tioner
663	1079		and the patient regarding the patient-provider
664	1080		agreement of the patient,
665		-
666	1081		c. establish the rights of the patient in association
667	1082		with treatment and the oblig ations of the patient in
	1083	+
	1084	+	SB249 HFLR Page 22
	1085	+	BOLD FACE denotes Committee Amendments. 1
	1086	+	2
	1087	+	3
	1088	+	4
	1089	+	5
	1090	+	6
	1091	+	7
	1092	+	8
	1093	+	9
	1094	+	10
	1095	+	11
	1096	+	12
	1097	+	13
	1098	+	14
	1099	+	15
	1100	+	16
	1101	+	17
	1102	+	18
	1103	+	19
	1104	+	20
	1105	+	21
	1106	+	22
	1107	+	23
	1108	+	24
	1109	+
668	1110		relation to the responsible use, discontinuation of
669	1111		use, and storage of opioid drugs including any
670	1112		restrictions on the refill of p rescriptions or the
671	1113		acceptance of opioid prescriptions from practitioners,
672		-
673	1114		d. identify the specific m edications and other modes of
674	1115		treatment including physical therapy or exercise,
675	1116		relaxation or psychological counseling, that are
676	1117		included as a part of the patient-provider agreement,
677		-
678	1118		e. specify the measures the practitioner may employ to
679	1119		monitor the compliance of the patient including, but
680	1120		not limited to, random specimen screens and pill
681	1121		counts, and
682		-
683	1122		f. delineate the process for terminating the agreement
684	1123		including the consequences if the p ractitioner has
685	1124		reason to believe that the patient is not complying
686	1125		with the terms of the agreement. Compliance with the
687	1126		“consent items” shall constitute a valid, informed
688	1127		consent for opioid therapy. The practitioner shall be
689	1128		held harmless from civil lit igation for failure to
690	1129		treat pain if the event occurs because of nonad herence
691	1130		by the patient with any of the provisions of the
692	1131		patient-provider agreement;
693		-
694	1132		46. “Serious illness” means a medical illness or physical
695	1133		injury or condition that substantially aff ects quality of life for
	1134	+
	1135	+	SB249 HFLR Page 23
	1136	+	BOLD FACE denotes Committee Amendments. 1
	1137	+	2
	1138	+	3
	1139	+	4
	1140	+	5
	1141	+	6
	1142	+	7
	1143	+	8
	1144	+	9
	1145	+	10
	1146	+	11
	1147	+	12
	1148	+	13
	1149	+	14
	1150	+	15
	1151	+	16
	1152	+	17
	1153	+	18
	1154	+	19
	1155	+	20
	1156	+	21
	1157	+	22
	1158	+	23
	1159	+	24
	1160	+
696	1161		more than a short period of time. “Serious illness” Serious illness
697		-
698		-	ENR. S. B. NO. 249 Page 17
699	1162		includes, but is not limited to, Alzheimer ’s disease or related
700	1163		dementias, lung disease, cancer, heart failure, renal failure, live r
701	1164		failure or chronic, unremitti ng or intractable pain such as
702	1165		neuropathic pain;
703		-
704	1166		47. “Surgical procedure” means a procedure that is performed
705	1167		for the purpose of structurally altering the human bo dy by incision
706	1168		or destruction of tissues as part of the pract ice of medicine. This
707	1169		term includes the diagnostic or therapeutic treatment of conditions
708	1170		or disease processes by us e of instruments such as lasers,
709	1171		ultrasound, ionizing, radiation, scalpels, pr obes or needles that
710	1172		cause localized alteration or transporta tion of live human tissue by
711	1173		cutting, burning, vaporizing, freezing, suturing, probing or
712	1174		manipulating by closed redu ction for major dislocations or
713	1175		fractures, or otherwise altering by any mechan ical, thermal, light-
714	1176		based, electromagnetic or chemical means ; and
715		-
716	1177		48. “Harm-reduction services” means programs established to:
717		-
718	1178		a. reduce the spread of infectious diseases relat ed to
719	1179		injection drug use,
720		-
721	1180		b. reduce drug dependency, overdose deaths and assoc iated
722	1181		complications, and
723		-
724	1182		c. increase safe recovery and dispos al of used syringes
725	1183		and sharp waste; and
	1184	+
	1185	+	SB249 HFLR Page 24
	1186	+	BOLD FACE denotes Committee Amendments. 1
	1187	+	2
	1188	+	3
	1189	+	4
	1190	+	5
	1191	+	6
	1192	+	7
	1193	+	8
	1194	+	9
	1195	+	10
	1196	+	11
	1197	+	12
	1198	+	13
	1199	+	14
	1200	+	15
	1201	+	16
	1202	+	17
	1203	+	18
	1204	+	19
	1205	+	20
	1206	+	21
	1207	+	22
	1208	+	23
	1209	+	24
726	1210
727	1211		49. “Palliative care” means a specialized medical service for
728	1212		people of any age and at any stage of a serious illness or life -
729	1213		altering medical event that focuses on navigating complex medical
730	1214		decisions while provid ing patient autonomy and access to
731	1215		information. Utilizing a holistic and interdisciplinary team
732	1216		approach, palliative care addresses physical, intellectual,
733	1217		emotional, social, and spiritual needs . Palliative care may be
734	1218		provided in the inpatient, outpatie nt, or home care setting and
735	1219		strives to improve quality of life for both the patient and the
736	1220		family.
737		-
738	1221		SECTION 2. AMENDATORY 63 O.S. 2021, Section 2 -309, as
739	1222		last amended by Section 1, Chapter 259, O.S.L 2021, is amended to
740	1223		read as follows:
741		-
742		-	ENR. S. B. NO. 249 Page 18
743		-
744	1224		Section 2-309. A. 1. Except for dosages medically required
745	1225		for a period not to exceed forty -eight (48) hours which are
746	1226		administered by or on direction of a practitioner, other than a
747	1227		pharmacist, or medication dispensed directly by a practitioner,
748	1228		other than a pharmacis t, to an ultimate user, no controlled
749	1229		dangerous substance included in Schedule II , which is a prescription
750	1230		drug as determined und er regulation promulgated by the Board of
751	1231		Pharmacy, shall be dispensed without an electronic prescription of a
752	1232		practitioner; provided, that in emergency situations, as prescribed
753	1233		by the Board of Pharmacy by regulation, s uch drug may be dispensed
754	1234		upon oral prescription reduced promptly to writing a nd filed by the
	1235	+
	1236	+	SB249 HFLR Page 25
	1237	+	BOLD FACE denotes Committee Amendments. 1
	1238	+	2
	1239	+	3
	1240	+	4
	1241	+	5
	1242	+	6
	1243	+	7
	1244	+	8
	1245	+	9
	1246	+	10
	1247	+	11
	1248	+	12
	1249	+	13
	1250	+	14
	1251	+	15
	1252	+	16
	1253	+	17
	1254	+	18
	1255	+	19
	1256	+	20
	1257	+	21
	1258	+	22
	1259	+	23
	1260	+	24
	1261	+
755	1262		pharmacist in a manner to be prescribed by rules and regulations of
756	1263		the Director of the Oklahoma State Bureau of Narcotics and Dangerous
757	1264		Drugs Control.
758		-
759	1265		2. Electronic prescribing shall be utilized f or Schedules II,
760	1266		III, IV and V, subject to the requirements set forth i n 21 CFR,
761	1267		Section 1311 et seq.
762		-
763	1268		3. An electronic prescri ption with electronic signature may
764	1269		serve as an original prescription, subject to the require ments set
765	1270		forth in 21 CFR, Section 1 311 et seq.
766		-
767	1271		4. Prescriptions shall be ret ained in conformity with the
768	1272		requirements of this section and Section 2-307 of this title. No
769	1273		prescription for a Schedule II substance may be refilled.
770		-
771	1274		5. The electronic prescr iption requirement provided for in t his
772	1275		section shall not apply to prescriptio ns for controlled dangerous
773	1276		substances issued by any of the following:
774		-
775	1277		a. a person licensed to practice veterinary medicine,
776		-
777	1278		b. a practitioner who experiences temporary technolog ical
778	1279		or electrical failure or other extenuating
779	1280		circumstance that prevents the prescription from being
780	1281		transmitted electronically; provided, however, that
781	1282		the practitioner documents the reason for this
782	1283		exception in the medical record of the patient,
783		-
784		-
785		-	ENR. S. B. NO. 249 Page 19
786	1284		c. a practitioner, other than a pharmacist , who dispenses
787	1285		directly to an ultimate us er,
	1286	+
	1287	+	SB249 HFLR Page 26
	1288	+	BOLD FACE denotes Committee Amendments. 1
	1289	+	2
	1290	+	3
	1291	+	4
	1292	+	5
	1293	+	6
	1294	+	7
	1295	+	8
	1296	+	9
	1297	+	10
	1298	+	11
	1299	+	12
	1300	+	13
	1301	+	14
	1302	+	15
	1303	+	16
	1304	+	17
	1305	+	18
	1306	+	19
	1307	+	20
	1308	+	21
	1309	+	22
	1310	+	23
	1311	+	24
788	1312
789	1313		d. a practitioner who ord ers a controlled dangerous
790	1314		substance to be administered through an on-site
791	1315		pharmacy in:
792		-
793	1316		(1) a hospital as defined in Section 1 -701 of this
794	1317		title,
795		-
796	1318		(2) a nursing facility as defined in Se ction 1-1902
797	1319		of this title,
798		-
799	1320		(3) a hospice inpatient facility as defined in
800	1321		Section 1-860.2 of this title,
801		-
802	1322		(4) an outpatient dialysis f acility,
803		-
804	1323		(5) a continuum of care facility as defined in
805	1324		Section 1-890.2 of this title, or
806		-
807	1325		(6) a penal institution listed i n Section 509 of
808	1326		Title 57 of the Oklahoma Statutes,
809		-
810	1327		e. a practitioner who orders a controlled dangerous
811	1328		substance to be administered t hrough a hospice program
812	1329		as defined in including but not limited to a hospice
813	1330		program that provides hospice services in the private
814	1331		residence of a patient or in a long-term care facility
815	1332		where the patient resides. As used in this
816	1333		subparagraph, “hospice program” has the same meaning
817	1334		as provided by Section 1-860.2 of this title,
818		-
819	1335		f. a practitioner who writes a prescription to be
820	1336		dispensed by a pharmacy located on federal property,
	1337	+
	1338	+	SB249 HFLR Page 27
	1339	+	BOLD FACE denotes Committee Amendments. 1
	1340	+	2
	1341	+	3
	1342	+	4
	1343	+	5
	1344	+	6
	1345	+	7
	1346	+	8
	1347	+	9
	1348	+	10
	1349	+	11
	1350	+	12
	1351	+	13
	1352	+	14
	1353	+	15
	1354	+	16
	1355	+	17
	1356	+	18
	1357	+	19
	1358	+	20
	1359	+	21
	1360	+	22
	1361	+	23
	1362	+	24
	1363	+
821	1364		provided the practitioner documents the reason f or
822	1365		this exception in the medic al record of the patient,
823	1366		or
824		-
825	1367		g. a practitioner that has received a waiv er or extension
826	1368		from his or her licensing board.
827		-
828		-
829		-	ENR. S. B. NO. 249 Page 20
830	1369		6. Electronic prescriptions shall not be utilized under the
831	1370		following circumstances:
832		-
833	1371		a. compound prescriptions containing two or more
834	1372		commercially available products or two or more active
835	1373		pharmaceutical ingredients,
836		-
837	1374		b. compounded infusion prescriptions containing two or
838	1375		more commercially available products or two or mo re
839	1376		active pharmaceutical ingredients,
840		-
841	1377		c. prescriptions issued under app roved research
842	1378		protocols, or
843		-
844	1379		d. if the practitioner determines that an electronic
845	1380		prescription cannot be issued in a timely manner and
846	1381		the condition of the patient is at risk.
847		-
848	1382		7. A pharmacist who receives a written, oral or f acsimile
849	1383		prescription shall no t be required to verify that the prescription
850	1384		falls under one of the ex ceptions provided for in paragraph 6 of
851	1385		this subsection. Pharmacists may cont inue to dispense medications
852	1386		from otherwise valid written, oral or facsimile prescriptions that
853	1387		are consistent with the provisions of this section.
854	1388
	1389	+	SB249 HFLR Page 28
	1390	+	BOLD FACE denotes Committee Amendments. 1
	1391	+	2
	1392	+	3
	1393	+	4
	1394	+	5
	1395	+	6
	1396	+	7
	1397	+	8
	1398	+	9
	1399	+	10
	1400	+	11
	1401	+	12
	1402	+	13
	1403	+	14
	1404	+	15
	1405	+	16
	1406	+	17
	1407	+	18
	1408	+	19
	1409	+	20
	1410	+	21
	1411	+	22
	1412	+	23
	1413	+	24
	1414	+
855	1415		8. Practitioners shall indica te in the health record of a
856	1416		patient that an exception to the electronic presc ription requirement
857	1417		was utilized.
858		-
859	1418		9. All prescriptions issued pursuant to pa ragraphs 5 and 6 of
860	1419		this subsection shall be issued on an official prescription form
861	1420		provided by the Oklahoma State Bureau of Narcotics and Dangerous
862	1421		Drugs Control.
863		-
864	1422		10. a. Effective January 1, 2020, practitioners s hall
865	1423		register with the Oklahoma State Bur eau of Narcotics
866	1424		and Dangerous Drugs Control in order to be issued
867	1425		official prescription forms. Such registration shall
868	1426		include, but not be limited to, the primary address
869	1427		and the address of each place of business to be
870	1428		imprinted on official prescription forms. Any change
871	1429		to a registered practitioner’s registered address
872		-
873		-	ENR. S. B. NO. 249 Page 21
874	1430		shall be promptly reported to the practitioner’s
875	1431		licensing board and the Bureau by the practitioner in
876	1432		a manner approved by the Bureau.
877		-
878	1433		b. A practitioner’s registration shall be without f ee and
879	1434		subject to approval by the Bureau. Such registration
880	1435		shall be valid for a period of two (2) ye ars and may
881	1436		be denied, suspended or revoked by the Bureau upon a
882	1437		finding by the Bureau or licensing board that th e
883	1438		registered practitioner has had any lic ense to
	1439	+
	1440	+	SB249 HFLR Page 29
	1441	+	BOLD FACE denotes Committee Amendments. 1
	1442	+	2
	1443	+	3
	1444	+	4
	1445	+	5
	1446	+	6
	1447	+	7
	1448	+	8
	1449	+	9
	1450	+	10
	1451	+	11
	1452	+	12
	1453	+	13
	1454	+	14
	1455	+	15
	1456	+	16
	1457	+	17
	1458	+	18
	1459	+	19
	1460	+	20
	1461	+	21
	1462	+	22
	1463	+	23
	1464	+	24
	1465	+
884	1466		practice a medical pro fession revoked or suspended by
885	1467		any state or federal agency.
886		-
887	1468		c. Where the Bureau has revoked the registration of a
888	1469		registered practitioner, the Bureau may revoke or
889	1470		cancel any official prescription forms in the
890	1471		possession of the registered practitioner. A ny
891	1472		revocation or any suspension shall require the
892	1473		registered practitione r to return all unused official
893	1474		prescription forms to the Bureau within fiftee n (15)
894	1475		calendar days after the date of the written
895	1476		notification.
896		-
897	1477		d. A practitioner that has had any licens e to practice
898	1478		terminated, revoked or suspended by a state or federal
899	1479		agency may, upon restoration of such license or
900	1480		certificate, register to be issue d official
901	1481		prescription forms.
902		-
903	1482		11. a. Except as provided in subparagraph f of this
904	1483		paragraph, the Bureau shall issue official
905	1484		prescription forms free of charge only to registered
906	1485		practitioners in this state. Such forms shall not be
907	1486		transferable. The numb er of official prescription
908	1487		forms issued to a registered practitioner at an y time
909	1488		shall be at the discret ion of the Bureau.
910	1489
	1490	+	SB249 HFLR Page 30
	1491	+	BOLD FACE denotes Committee Amendments. 1
	1492	+	2
	1493	+	3
	1494	+	4
	1495	+	5
	1496	+	6
	1497	+	7
	1498	+	8
	1499	+	9
	1500	+	10
	1501	+	11
	1502	+	12
	1503	+	13
	1504	+	14
	1505	+	15
	1506	+	16
	1507	+	17
	1508	+	18
	1509	+	19
	1510	+	20
	1511	+	21
	1512	+	22
	1513	+	23
	1514	+	24
	1515	+
911	1516		b. Official prescription forms issued to a registered
912	1517		practitioner shall be imprinted only with the primary
913	1518		address and other addres ses listed on the registration
914	1519		of the practitioner. Such prescriptions sha ll be sent
915		-
916		-	ENR. S. B. NO. 249 Page 22
917	1520		only to the primary address of the registered
918	1521		practitioner.
919		-
920	1522		c. Official prescription forms i ssued to a registered
921	1523		practitioner shall be used only by the practitioner to
922	1524		whom they are issued.
923		-
924	1525		d. The Bureau may revoke or cancel official prescripti on
925	1526		forms in possession of regi stered practitioners when
926	1527		the license of such practitioner is suspended,
927	1528		terminated or revoked.
928		-
929	1529		e. Official prescription forms of registered
930	1530		practitioners who are deceased or who no lon ger
931	1531		prescribe shall be returned to the Bu reau at a
932	1532		designated address. If the registered practitioner is
933	1533		deceased, it is the responsibility of the registered
934	1534		practitioner’s estate or lawful designee to return
935	1535		such forms.
936		-
937	1536		f. The Bureau may issue official p rescription forms to
938	1537		employees or agents of the Bureau and other govern ment
939	1538		agencies for the purpose of preventing, identifying,
940	1539		investigating and prosecuting unacceptable or illegal
	1540	+
	1541	+	SB249 HFLR Page 31
	1542	+	BOLD FACE denotes Committee Amendments. 1
	1543	+	2
	1544	+	3
	1545	+	4
	1546	+	5
	1547	+	6
	1548	+	7
	1549	+	8
	1550	+	9
	1551	+	10
	1552	+	11
	1553	+	12
	1554	+	13
	1555	+	14
	1556	+	15
	1557	+	16
	1558	+	17
	1559	+	18
	1560	+	19
	1561	+	20
	1562	+	21
	1563	+	22
	1564	+	23
	1565	+	24
	1566	+
941	1567		practices by providers and other person s and assisting
942	1568		in the recovery of overpayments under any program
943	1569		operated by the state or paid for with state funds.
944	1570		Such prescription forms shall be issued for this
945	1571		purpose only to individuals who are authorized to
946	1572		conduct investigations on behalf of th e Bureau or
947	1573		other government agenc ies as part of their official
948	1574		duties. Individuals and agencies receivi ng such
949	1575		prescription forms for this purpose shall provide
950	1576		appropriate assurances to the Bureau that adequate
951	1577		safeguards and security measures are in pl ace to
952	1578		prevent the use of such prescription forms for
953	1579		anything other than o fficial government purposes.
954		-
955	1580		12. a. Adequate safeguards and security measures shall be
956	1581		undertaken by registered practitioners holding
957	1582		official prescription forms to assure against t he
958	1583		loss, destruction, theft or un authorized use of the
959		-
960		-	ENR. S. B. NO. 249 Page 23
961	1584		forms. Registered practitioners shall maintain a
962	1585		sufficient but not excessive supply of such forms in
963	1586		reserve.
964		-
965	1587		b. Registered practitioners shall immediately notify the
966	1588		Bureau, in a manner designated b y the Bureau, upon
967	1589		their knowledge of the loss, destruction, theft or
968	1590		unauthorized use of any official p rescription forms
	1591	+
	1592	+	SB249 HFLR Page 32
	1593	+	BOLD FACE denotes Committee Amendments. 1
	1594	+	2
	1595	+	3
	1596	+	4
	1597	+	5
	1598	+	6
	1599	+	7
	1600	+	8
	1601	+	9
	1602	+	10
	1603	+	11
	1604	+	12
	1605	+	13
	1606	+	14
	1607	+	15
	1608	+	16
	1609	+	17
	1610	+	18
	1611	+	19
	1612	+	20
	1613	+	21
	1614	+	22
	1615	+	23
	1616	+	24
	1617	+
969	1618		issued to them, as well as the failure to receive
970	1619		official prescription forms within a reasonable time
971	1620		after ordering them from the Bu reau.
972		-
973	1621		c. Registered practitioners shall immediately notify the
974	1622		Bureau upon their knowledge of any divers ion or
975	1623		suspected diversion of drugs pursuant to the loss,
976	1624		theft or unauthorized use of prescriptions.
977		-
978	1625		B. 1. Except for dosages medically required for a period not
979	1626		to exceed seventy-two (72) hours which are administered by or on
980	1627		direction of a practitione r, other than a pharmacist, or medication
981	1628		dispensed directly by a practiti oner, other than a pharmacist, to an
982	1629		ultimate user, no controlled dangerous su bstance included in
983	1630		Schedule III or IV, which is a prescription drug as de termined under
984	1631		regulation promulgated by the Board of Pharmacy, shall be dispensed
985	1632		without an electronic prescription.
986		-
987	1633		2. Any prescription for a controlled dangerous substance in
988	1634		Schedule III, IV or V may not be fi lled or refilled more than six
989	1635		(6) months after the date thereof or be refilled more than five
990	1636		times after the date of the prescription, unless r enewed by the
991	1637		practitioner.
992		-
993	1638		C. Whenever it appears to the Director of the Okl ahoma State
994	1639		Bureau of Narcotics a nd Dangerous Drugs Control that a drug no t
995	1640		considered to be a prescript ion drug under existing state law or
996	1641		regulation of the Board of Pharmacy s hould be so considered because
	1642	+
	1643	+	SB249 HFLR Page 33
	1644	+	BOLD FACE denotes Committee Amendments. 1
	1645	+	2
	1646	+	3
	1647	+	4
	1648	+	5
	1649	+	6
	1650	+	7
	1651	+	8
	1652	+	9
	1653	+	10
	1654	+	11
	1655	+	12
	1656	+	13
	1657	+	14
	1658	+	15
	1659	+	16
	1660	+	17
	1661	+	18
	1662	+	19
	1663	+	20
	1664	+	21
	1665	+	22
	1666	+	23
	1667	+	24
	1668	+
997	1669		of its abuse potential, the Director shall so a dvise the Board of
998	1670		Pharmacy and furnish to the Board all available data re levant
999	1671		thereto.
1000		-
1001	1672		D. 1. “Prescription”, as used in this section, means a
1002	1673		written, oral or electronic ord er by a practitioner to a pharmacist
1003		-
1004		-	ENR. S. B. NO. 249 Page 24
1005	1674		for a controlled dangerous substance for a particular patient, which
1006	1675		specifies the date of its issue, and the full name and address of
1007	1676		the patient and, if the controlled dangerous substance is prescribed
1008	1677		for an animal, the species of the animal, the name and quantity of
1009	1678		the controlled dangerous s ubstance prescribed, the directio ns for
1010	1679		use, the name and address of the o wner of the animal and, if
1011	1680		written, the signature of the practitioner.
1012		-
1013	1681		2. “Registered practitioner ”, as used in this section, means a
1014	1682		licensed practitioner duly registered with the Oklahoma State Bureau
1015	1683		of Narcotics and Dangerous Drugs Control to be issue d official
1016	1684		prescription forms.
1017		-
1018	1685		E. No person shall solicit, dispense, receive or deliver any
1019	1686		controlled dangerous substance through the mail, unless the ultimate
1020	1687		user is personally k nown to the practitioner and circ umstances
1021	1688		clearly indicate such method of delivery is in the best inter est of
1022	1689		the health and welfare of the ultimate user.
1023		-
1024	1690		SECTION 3. It being immediately necessary for the pr eservation
1025	1691		of the public peace, health or safety, an emergency i s hereby
	1692	+
	1693	+	SB249 HFLR Page 34
	1694	+	BOLD FACE denotes Committee Amendments. 1
	1695	+	2
	1696	+	3
	1697	+	4
	1698	+	5
	1699	+	6
	1700	+	7
	1701	+	8
	1702	+	9
	1703	+	10
	1704	+	11
	1705	+	12
	1706	+	13
	1707	+	14
	1708	+	15
	1709	+	16
	1710	+	17
	1711	+	18
	1712	+	19
	1713	+	20
	1714	+	21
	1715	+	22
	1716	+	23
	1717	+	24
	1718	+
1026	1719		declared to exist, by reason whe reof this act shall take effec t and
1027	1720		be in full force from and after its passage and approval.
1028	1721
1029		-
1030		-	ENR. S. B. NO. 249 Page 25
1031		-	Passed the Senate the 28th day of February, 2023.
1032		-
1033		-
1034		-
1035		-	Presiding Officer of the Senate
1036		-
1037		-
1038		-	Passed the House of Representatives the 19th day of April, 2023.
1039		-
1040		-
1041		-
1042		-	Presiding Officer of the House
1043		-	of Representatives
1044		-
1045		-	OFFICE OF THE GOVERNOR
1046		-	Received by the Office of the Governor this _______ _____________
1047		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
1048		-	By: _______________________________ __
1049		-	Approved by the Governor of the State of Oklahoma this _____ ____
1050		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
1051		-
1052		-	_________________________________
1053		-	Governor of the State of Oklahoma
1054		-
1055		-
1056		-	OFFICE OF THE SECRETARY OF STATE
1057		-	Received by the Office of the Secretary of State this _______ ___
1058		-	day of __________________, 20 _______, at _______ o'clock _______ M.
1059		-	By: _______________________________ __
	1722	+	COMMITTEE REPORT BY: COMMITTEE ON HEALTH SERVICES AND LONG -TERM
	1723	+	CARE, dated 04/04/2023 - DO PASS.